Ghost Tree Capital, LLC
Reported holdings as of Q3 2024, from 25 quarterly filings.
This filer last reported in Q3 2024; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| SPDR SERIES TRUST OPT | XBI | $29.6M | options only | - | new | OPTIONS | |
| BIOHAVEN LTD OPT | BHVN | $17.4M | 348,778 | - | new | NEW | |
| SAREPTA THERAPEUTICS INC | SRPT | $15.0M | 120,000 | +1.81pp | 12q | +118.2%+$8.1M | |
| NOVO-NORDISK A S | NVO | $13.1M | 110,000 | - | new | NEW | |
| BLUEPRINT MEDICINES CORP | BPMC | $12.9M | 140,000 | +2.56pp | 3q | +250.0%+$9.2M | |
| AXSOME THERAPEUTICS INC | AXSM | $12.1M | 135,000 | -0.12pp | 11q | -10.0%-$1.3M | |
| TARSUS PHARMACEUTICALS INC | TARS | $11.5M | 350,000 | +1.48pp | 14q | +48.9%+$3.8M | |
| PERSPECTIVE THERAPEUTICS INC | CATX | $10.0M | 750,000 | +0.14pp | 2q | -18.9%-$2.3M | |
| CG ONCOLOGY INC | CGON | $9.4M | 250,000 | +0.28pp | 3q | -3.8%-$377.3K | |
| ROIVANT SCIENCES LTD | ROIV | $9.2M | 800,000 | -0.52pp | 6q | -20.0%-$2.3M | |
| VAXCYTE INC | PCVX | $9.1M | 80,000 | -0.79pp | 14q | -46.7%-$8.0M | |
| INSMED INC OPT | INSM | $9.1M | 75,000 | -2.80pp | 3q | +15.4%+$1.2M | |
| VIKING THERAPEUTICS INC | VKTX | $8.9M | 140,000 | +1.10pp | 3q | +47.4%+$2.8M | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $8.7M | 450,000 | +0.37pp | 3q | +28.6%+$1.9M | |
| JANUX THERAPEUTICS INC | JANX | $8.6M | 190,000 | +1.95pp | 2q | +280.0%+$6.4M | |
| CORBUS PHARMACEUTICALS HLDGS OPT | CRBP | $7.8M | 160,000 | -0.11pp | 3q | -8.6%-$734.9K | |
| ASCENDIS PHARMA A/S | ASND | $7.8M | 52,500 | -1.34pp | 2q | -39.5%-$5.1M | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $7.7M | 150,000 | -1.05pp | 5q | -37.5%-$4.6M | |
| SOLENO THERAPEUTICS INC | SLNO | $7.6M | 150,000 | -1.55pp | 4q | -50.0%-$7.6M | |
| TG THERAPEUTICS INC | TGTX | $7.3M | 310,000 | -0.60pp | 7q | -38.0%-$4.4M | |
| REZOLUTE INC | RZLT | $7.2M | 1,474,995 | +0.25pp | 2q | +3.8%+$259.4K | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $6.8M | 375,000 | +0.11pp | 6q | -37.5%-$4.1M | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $6.5M | 128,411 | -2.17pp | 7q | -57.2%-$8.7M | |
| OLEMA PHARMACEUTICALS INC | OLMA | $6.4M | 535,000 | +0.07pp | 3q | -2.7%-$179.1K | |
| IMMUNOVANT INC | IMVT | $6.1M | 215,000 | -0.30pp | 3q | -17.3%-$1.3M | |
| EDGEWISE THERAPEUTICS INC | EWTX | $5.2M | 195,000 | - | new | NEW | |
| REPLIMUNE GROUP INC | REPL | $4.9M | 450,000 | +0.22pp | 6q | HELD | |
| BRIDGEBIO PHARMA INC | BBIO | $4.5M | 175,000 | +0.24pp | 7q | +25.0%+$891.1K | |
| TAYSHA GENE THERAPIES INC | TSHA | $4.3M | 2,150,000 | +0.43pp | 5q | +72.0%+$1.8M | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $4.1M | 78,842 | -0.26pp | 3q | -32.8%-$2.0M | |
| ANNEXON INC | ANNX | $3.8M | 650,000 | +0.36pp | 2q | +109.7%+$2.0M | |
| KORRO BIO INC | KRRO | $3.7M | 110,000 | +0.05pp | 2q | +10.0%+$334.2K | |
| DYNE THERAPEUTICS INC | DYN | $3.6M | 100,000 | - | new | NEW | |
| ARVINAS INC | ARVN | $3.6M | 145,000 | +0.45pp | 4q | +93.3%+$1.7M | |
| HELIX ACQUISITION CORP II | HLXB | $3.1M | 300,000 | -0.01pp | 3q | HELD | |
| NUVATION BIO INC | NUVB | $3.1M | 1,350,000 | -0.12pp | 2q | +17.4%+$458.0K | |
| SAVARA INC | SVRA | $3.1M | 725,000 | -0.40pp | 4q | -31.0%-$1.4M | |
| TENAYA THERAPEUTICS INC | TNYA | $2.9M | 1,500,000 | -0.44pp | 3q | +11.1%+$289.5K | |
| REGENXBIO INC | RGNX | $2.8M | 265,000 | +0.22pp | 3q | +55.9%+$996.5K | |
| CORVUS PHARMACEUTICALS INC | CRVS | $2.6M | 500,000 | - | new | NEW | |
| ABSCI CORPORATION | ABSI | $2.1M | 550,000 | - | new | NEW | |
| NEUROGENE INC | NGNE | $2.1M | 50,000 | -0.16pp | 3q | -28.6%-$839.2K | |
| CAPRICOR THERAPEUTICS INC | CAPR | $1.9M | 125,000 | - | new | NEW | |
| APELLIS PHARMACEUTICALS INC | APLS | $1.9M | 65,000 | -1.06pp | 13q | -51.9%-$2.0M | |
| SUMMIT THERAPEUTICS INC | SMMT | $1.9M | 85,000 | - | new | NEW | |
| SPYRE THERAPEUTICS INC | SYRE | $1.8M | 60,000 | -1.31pp | 3q | -76.0%-$5.6M | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $1.7M | 75,000 | -1.88pp | 15q | -87.2%-$11.7M | |
| PROQR THRAPEUTICS N V | PRQR | $1.6M | 887,700 | +0.02pp | 2q | -1.4%-$22.4K | |
| ATYR PHARMA INC | ATYR | $1.4M | 800,000 | +0.03pp | 3q | HELD | |
| LARIMAR THERAPEUTICS INC | LRMR | $1.3M | 200,000 | - | new | NEW | |
| ENGENE HOLDINGS INC | ENGN | $1.1M | 160,898 | -0.92pp | 3q | -61.7%-$1.7M | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $1.1M | 325,000 | - | new | NEW |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $275.9M | 83.3% |
| Not classified | $55.2M | 16.7% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | $331.0M | 52 | 11 | 16 | 22 | 19 | 42.4% | 45 |
| Q2 2024 | $319.3M | 60 | 11 | 22 | 18 | 19 | 43.5% | 45 |
| Q1 2024 | $361.3M | 68 | 29 | 24 | 11 | 10 | 41.0% | 45 |
| Q4 2023 | $305.9M | 49 | 13 | 13 | 18 | 27 | 59.3% | 45 |
| Q3 2023 | $304.1M | 63 | 18 | 13 | 17 | 12 | 48.1% | 45 |
| Q2 2023 | $302.9M | 57 | 15 | 24 | 14 | 12 | 52.1% | 45 |
| Q1 2023 | $338.3M | 54 | 26 | 14 | 12 | 7 | 51.1% | 45 |
| Q4 2022 | $234.2M | 35 | 8 | 6 | 20 | 11 | 57.9% | 45 |
| Q3 2022 | $356.3M | 38 | 12 | 11 | 12 | 5 | 60.6% | 45 |
| Q2 2022 | $192.0M | 31 | 5 | 10 | 11 | 15 | 59.4% | 46 |
| Q1 2022 | $460.8M | 41 | 7 | 8 | 20 | 11 | 75.2% | 46 |
| Q4 2021 | $279.0M | 45 | 9 | 18 | 13 | 22 | 47.9% | 47 |
| Q3 2021 | $342.0M | 58 | 18 | 8 | 15 | 11 | 43.0% | 46 |
| Q2 2021 | $363.8M | 51 | 15 | 9 | 11 | 13 | 49.2% | 42 |
| Q1 2021 | $425.5M | 49 | 16 | 10 | 11 | 9 | 49.0% | 133 |
| Q4 2020 | $448.8M | 42 | 13 | 9 | 14 | 17 | 52.2% | 49 |
| Q3 2020 | $346.0M | 46 | 16 | 14 | 9 | 12 | 58.1% | 47 |
| Q2 2020 | $379.0M | 42 | 9 | 10 | 15 | 14 | 49.3% | 45 |
| Q1 2020 | $377.0M | 47 | 14 | 10 | 18 | 16 | 63.2% | 45 |
| Q4 2019 | $525.1M | 49 | 20 | 13 | 13 | 13 | 54.8% | 100 |
| Q3 2019 | $392.5M | 42 | 12 | 10 | 15 | 12 | 56.4% | 192 |
| Q2 2019 | $482.1M | 42 | 14 | 7 | 12 | 10 | 62.3% | 284 |
| Q1 2019 | $382.8M | 38 | 11 | 10 | 9 | 10 | 55.3% | 375 |
| Q4 2018 | $275.5M | 37 | 8 | 8 | 10 | 22 | 61.1% | 465 |
| Q3 2018 | $470.5M | 51 | 0 | 0 | 0 | 0 | 53.7% | 557 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.